BillionToOne Announces Launch Of Northstar PGx And Northstar Select CH

Northstar PGx™ and Northstar Select CH™ extend clinical insight and utility of Northstar Select® all from the same blood-draw

MENLO PARK, Calif., Feb. 10, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar PGx and Northstar Select CH. Northstar PGx and Northstar CH are add-on applications for Northstar Select, the most sensitive therapy selection liquid biopsy for advanced solid tumors, as demonstrated in a head-to-head clinical study, proven to uncover 50%+ more clinically actionable alterations.1 The launch expands the Northstar platform beyond genomic profiling to address chemotherapy safety and clonal hematapoeisis—two critical decision points in selecting the right therapy for patients.